CA
AXSM icon

Cannon Advisors’s Axsome Therapeutics AXSM Stock Holding History

Cannon Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.21M Buy
7,758
+1,802
+30% +$392K 0.7% 40
2026
Q2 		$1.4M Buy
+5,956
New +$1.29M 0.85% 38

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Cannon Advisors's AXSM Position: Q3 2026 in Review

Cannon Advisors increased its Axsome Therapeutics (AXSM) stake by 30% in Q3 2026, buying an estimated $392K and bringing the position to 7,758 shares worth $1.21M. The position accounts for 0.7% of the portfolio, ranked #40.

Cannon Advisors first reported a position in AXSM in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.4M in Q2 2026. 38 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Cannon Advisors held 7,758 shares of Axsome Therapeutics worth $1.21M as of Q3 2026.
  • Cannon Advisors bought 1,802 Axsome Therapeutics shares in Q3 2026, an estimated $392K.
  • Axsome Therapeutics made up 0.7% of Cannon Advisors's portfolio in Q3 2026, its #40 holding.
  • Cannon Advisors first reported a position in Axsome Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Cannon Advisors's Axsome Therapeutics position peaked at $1.4M in Q2 2026.
  • 38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Cannon Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.